MedDataX Logo

Intraoperative Different Concentrations Oxygen And Oxidatıve Stress Markers

NCT ID: NCT05099523

Last Updated: 2021-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study was to assess the effect of intraoperative oxygen (O2), which was applied at 30% and 50% concentrations on patients who had undergone septoplasty surgery, on Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Oxidative Stress Index (OSI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Hyperoxia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

oxidative stress markers general anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group I

50%Fio2

Group Type PLACEBO_COMPARATOR

taking arterial blood sample through the injector

Intervention Type PROCEDURE

taking blood samples from patients applied with different oxygen concentrations

group II

30%Fio2

Group Type ACTIVE_COMPARATOR

taking arterial blood sample through the injector

Intervention Type PROCEDURE

taking blood samples from patients applied with different oxygen concentrations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

taking arterial blood sample through the injector

taking blood samples from patients applied with different oxygen concentrations

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged between 18-60 years,
* ASA I-II risk class with a minimum operative time of 1.5 hour(s) for whom septoplasty operation under elective conditions

Exclusion Criteria

* metabolic, endocrine, hepatic, cardiac, or renal diseases,
* malignancies and who used a drug with antioxidant properties such as vitamin E-C
* acetylcysteine in the last 48 hours,
* patients requiring intraoperative 100% O2 inhalation
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zonguldak Bulent Ecevit University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gamze Küçükosman

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zonguldak Bülent Ecevit University

Zonguldak, Kozlu, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/01

Identifier Type: -

Identifier Source: org_study_id